Ivonescimab for advanced skin angiosarcoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced or spreading skin angiosarcoma that cannot be removed by surgery.
- You have already received chemotherapy with paclitaxel or docetaxel.
- You have at least one tumor that can be measured (at least 1 cm on a scan or 2 cm on an X-ray).
- You are 18 years or older.
- You are in generally good health (able to do most daily activities without help, as judged by your doctor).
- Your kidney, liver, and blood cell counts are within acceptable limits based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Hear when a new Cutaneous Angiosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.